EUVIMEDEUVIMED entdecken
Crossref

Safety and efficacy of EUS-guided radiofrequency ablation of pancreatic tumors: largest mono-center study

J. M. Gonzalez, M. Gasmi, M. Barthet

Endoscopy · 01.04.2023 · 55 (S 02 S 02) · S122

DOI: 10.1055/s-0043-1765296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2023. Verfasst von J. M. Gonzalez und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Pancreatic radiofrequency under EUS (EUS-RFA) is an innovative technique but evaluated in limited series. The objectives were to evaluate the safety, the long-term efficacy, and identify predictive factors for outcomes.

Methods

Single-center retrospective study conducted on patients treated by EUS-RFA from 2015 to 2022 for pancreatic tumors. Treatment consisted of ≥ sessions of EUS-RFA with dedicated refrigerated needle (STARmed, Taewoong, Korea), after prophylactic measures. The safety was assessed using the AGREE classification, and patients were followed at least 2 years.

Results

107 EUS-RFA were performed, on 89 patients (median age 67 years). Lesions were IPMNs (38.2%) mucinous cystadenoma (7.9%), neuroendocrine tumors (34.8%), pancreatic metastasis (6.7%), adenocarcinomas (12.4%). Eleven patients (10.3% of procedures) had perioperative adverse events, mainly acute pancreatitis or febrile abdominal pain ≤ AGREE grade IIIa (4.7% grade IIIa), all with favorable outcome after conservative treatment. The absence of NSAIDs and prophylactic antibiotics were risk factors for complications (OR = 22.6 CI [1.8-281], p < 0.01). At 6 months, 1 year and at last follow-up, the response rate was 83.7%, 82.1% and 79.5% for IPMNs and cystadenomas, and 75.7%, 79.3% and 81.6% for NETs and 44.4% for pancreatic metastases, respectively. The efficacy for adenocarcinomas were about analgesia, with a response rate at 90%. A significant response at 6 months for NETs and IPMNs was predictive for final response.

Conclusions

EUS-RFA for precancerous pancreatic lesions or primary or secondary malignant lesions seems to be an alternative of choice with good long-term effectiveness. Publication History Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Gonzalez, J. M., Gasmi, M., & Barthet, M. (2023). Safety and efficacy of EUS-guided radiofrequency ablation of pancreatic tumors: largest mono-center study. Endoscopy, 55(S 02 S 02), S122. https://doi.org/10.1055/s-0043-1765296

Vancouver

Gonzalez JM, Gasmi M, Barthet M. Safety and efficacy of EUS-guided radiofrequency ablation of pancreatic tumors: largest mono-center study. Endoscopy. 2023;55(S 02 S 02):S122. doi:10.1055/s-0043-1765296

BibTeX
@article{Gonzalez2023,
  author = {Gonzalez, J. M. and Gasmi, M. and Barthet, M.},
  title = {Safety and efficacy of EUS-guided radiofrequency ablation of pancreatic tumors: largest mono-center study},
  journal = {Endoscopy},
  year = {2023},
  volume = {55},
  number = {S 02 S 02},
  pages = {S122},
  doi = {10.1055/s-0043-1765296}
}
Kostenlos starten →